Scott William Rowlinson is a notable inventor based in Zionsville, Indiana. He has made significant contributions to the field of biomedical research, particularly in the development of novel therapeutic proteins and antibodies. With a total of 3 patents to his name, Rowlinson's work has the potential to impact various medical treatments.

Latest Patents

Rowlinson's latest patents include innovative advancements in human BMP7 protein variants. This invention relates to novel variants of human BMP7 protein, which includes vectors and host cells for the propagation of nucleic acid sequences encoding these proteins. The methods disclosed in this patent aim to treat conditions such as cancer, cartilage damage, pain associated with osteoarthritis, and promote bone healing. Another significant patent involves TGF-beta binding antibodies, which provide high affinity antibodies that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. These antibodies are particularly useful for treating cell proliferative disorders in mammals.

Career Highlights

Rowlinson is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its innovative research and development in healthcare. His work at Eli Lilly has allowed him to collaborate with other talented professionals in the field.

Collaborations

Some of his notable coworkers include James David Pancook and Bryan Edward Jones. Their collective expertise contributes to the advancement of research and development within the company.

Conclusion

Scott William Rowlinson is a distinguished inventor whose work in biomedical research is paving the way for new therapeutic solutions. His patents reflect a commitment to improving healthcare outcomes through innovative science.

Profile summary based on public USPTO records.